Trial Profile
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 ANTIGEN VACCINE (SA4AG) IN ADULTS UNDERGOING ELECTIVE OPEN POSTERIOR SPINAL FUSION PROCEDURES WITH MULTILEVEL INSTRUMENTATION
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Staphylococcus aureus vaccine (Primary)
- Indications Postoperative infections; Staphylococcal infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms STRIVE
- Sponsors Pfizer; Pfizer Japan
- 01 May 2023 Primary endpoint has not been met. (SA4Ag efficacy in preventing postoperative S aureus bloodstream infection and/or deep incisional or organ/space SSI), as per Results published in the Clinical Infectious Diseases
- 01 May 2023 Results published in the Clinical Infectious Diseases
- 17 Aug 2020 Status changed to discontinued.